
Immuneering Corp (IMRX) Stock Forecast & Price Target
Immuneering Corp (IMRX) Analyst Ratings
Bulls say
Immuneering is a promising biopharmaceutical company with a BUY rating, supported by their innovative Disease Cancelling Technology platform and strong computational biology capabilities. Despite facing risks in clinical trials and competition, their potential breakthrough cancer treatment, atebimetinib, and other drug pipelines indicate a positive outlook for long-term profitability in the future. With a price target of $14 and projected profitability in 2035, Immuneering is a prime investment opportunity in the biopharmaceutical industry.
Bears say
Immuneering is heavily focused on developing MEK inhibitors and other oncology programs, with some promising early results. However, their reliance on this area puts them at risk if these drugs fail in clinical trials. Their current financials suggest a strong cash position, but it is uncertain if they will be able to achieve their projected peak market shares and sales for their drugs.
This aggregate rating is based on analysts' research of Immuneering Corp and is not a guaranteed prediction by Public.com or investment advice.
Immuneering Corp (IMRX) Analyst Forecast & Price Prediction
Start investing in Immuneering Corp (IMRX)
Order type
Buy in
Order amount
Est. shares
0 shares